Non-typeable Haemophilus influenzae–Moraxella catarrhalis vaccine for the prevention of exacerbations in chronic obstructive pulmonary disease: a multicentre, randomised, placebo-controlled, observer-blinded, proof-of-concept, phase 2b trial

医学 卡他莫拉菌 恶化 慢性阻塞性肺病 内科学 流感嗜血杆菌 安慰剂 慢性支气管炎 随机对照试验 免疫学 抗生素 生物 微生物学 病理 替代医学
作者
Stefan Andreas,Marco Testa,Laurent Boyer,Guy Brusselle,Wim Janssens,Edward Kerwin,Alberto Papi,Bonavuth Pek,Luís Puente‐Maestu,Dinesh Saralaya,Henrik Watz,Tom Wilkinson,Daniela Casula,Gennaro Di Maro,Maria Lattanzi,Luca Moraschini,Sonia Schoonbroodt,Annaelisa Tasciotti,Ashwani Kumar Arora,François Maltais
出处
期刊:The Lancet Respiratory Medicine [Elsevier BV]
卷期号:10 (5): 435-446 被引量:30
标识
DOI:10.1016/s2213-2600(21)00502-6
摘要

Background Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are associated with changes in the sputum microbiome, including an increased prevalence of pathogenic bacteria.Vaccination against the most frequent bacteria identified in AECOPD might reduce exacerbation frequency.We assessed the efficacy, safety, and immunogenicity of a candidate vaccine containing surface proteins from non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat) in patients with COPD.Methods This multicentre, randomised, observer-blinded, placebo-controlled, proof-of-concept, phase 2b trial recruited patients with stable COPD, moderate-to-very severe airflow limitation (Global Initiative for Chronic Obstructive Lung Disease [GOLD] stage 2, 3, or 4), at 67 clinical sites in Belgium, Canada, France, Germany, Italy, Spain, UK, and USA.Eligible patients were aged 40-80 years and had a history of at least one moderate or severe exacerbation in the previous year.Patients were allocated (1:1) using a minimisation algorithm to receive two intramuscular injections of NTHi-Mcat vaccine or placebo 60 days apart, in addition to standard care.The allocation algorithm considered age category, number of previous exacerbations, COPD severity at study entry, and country as minimisation factors, to guarantee treatment balance within each factor.Vaccine recipients and those responsible for evaluating study endpoints were masked to group allocation.In the analysis of efficacy, the primary outcome was the rate of any moderate or severe AECOPD occurring within a 1-year period, starting 1 month after the second dose in patients who received two vaccine doses (modified total vaccinated cohort).Safety was assessed in the total vaccinated cohort.The trial is registered with ClinicalTrials.gov,number NCT03281876, and is complete.Findings Between Nov 27, 2017, and Nov 30, 2018, 606 adults were enrolled and included in the total vaccinated cohort (304 in the NTHi-Mcat vaccine group, 302 in the placebo group); 571 received two doses and were included in the primary efficacy analysis (279 in the NTHi-Mcat vaccine group, 292 in the placebo group).23 participants dropped-out in the NTHi-Mcat vaccine group and 39 in the placebo group; this included 4 patients in the NTHi-Mcat vaccine group and 15 in the placebo group who withdrew from the study because of an adverse event.The primary analysis included 340 exacerbations (in follow-up time 102 123 days) in the NTHi-Mcat vaccine group and 333 (in 104 443 days) in the placebo group, with a yearly rate of moderate or severe AECOPD of 1•22 in the NTHi-Mcat vaccine group and 1•17 in the placebo group, with vaccine efficacy in reducing the yearly rate of moderate or severe AECOPD estimated to be zero (vaccine efficacy point estimate 2•26% [87% CI -18•27 to 11•58]; p=0•82).Solicited local adverse events were more frequent in the NTHi-Mcat vaccine group (216 [72%] of 301 patients) than with placebo (34 [11%] of 299 patients), and the frequency of solicited general adverse events was similar between groups (239 [79%] of 301 vs 235 [79%] of 299 patients).There was one death in the NTHi-Mcat vaccine group (acute respiratory failure, not related to vaccination) and ten in the placebo group (seven due in part to COPD or respiratory failure).There were 158 serious adverse events (89 [29%] of 304 patients) in the NTHi-Mcat vaccine group, not related to vaccination, and 214 (99 [33%] of 302 patients) in the placebo group.Interpretation NTHi-Mcat vaccine administered to patients with COPD did not show efficacy in reducing the yearly rate of moderate or severe exacerbations.No safety concerns were identified.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
沉默笑蓝发布了新的文献求助10
刚刚
熊大完成签到,获得积分10
刚刚
刚刚
脑洞疼的应助被001采纳,获得10
1秒前
沉默笑蓝发布了新的文献求助10
2秒前
2秒前
逃跑计划发布了新的文献求助10
2秒前
2秒前
沉默笑蓝发布了新的文献求助10
2秒前
沉默笑蓝发布了新的文献求助10
3秒前
沉默笑蓝发布了新的文献求助10
3秒前
3秒前
科研通AI6.4的应助被清秀送终采纳,获得10
3秒前
花花发布了新的文献求助10
3秒前
4秒前
沉默笑蓝发布了新的文献求助30
5秒前
5秒前
沉默笑蓝发布了新的文献求助10
5秒前
沉默笑蓝发布了新的文献求助10
5秒前
沉默笑蓝发布了新的文献求助10
5秒前
5秒前
Tuuuuu的应助被黄毛虎采纳,获得10
5秒前
沉默笑蓝发布了新的文献求助10
6秒前
6秒前
沉默笑蓝发布了新的文献求助10
6秒前
6秒前
沉默笑蓝发布了新的文献求助10
6秒前
汉堡包的应助被67采纳,获得10
6秒前
沉默笑蓝发布了新的文献求助10
6秒前
jianglai发布了新的文献求助200
6秒前
沉默笑蓝发布了新的文献求助80
7秒前
Simonn29完成签到,获得积分10
7秒前
7秒前
周周完成签到,获得积分10
8秒前
AoAoo完成签到 ,获得积分20
8秒前
8秒前
9秒前
聂志鹏发布了新的文献求助10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187226
求助须知:如何正确求助?哪些是违规求助? 9575395
关于积分的说明 21841040
捐赠科研通 7784958
什么是DOI,文献DOI怎么找? 3434935
关于科研通互助平台的介绍 2559355
邀请新用户注册赠送积分活动 2481808